News coverage about Mednax (NYSE:MD) has been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mednax earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.6789748026194 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

Shares of Mednax (MD) opened at 41.89 on Friday. The firm’s 50-day moving average price is $52.18 and its 200 day moving average price is $60.69. Mednax has a 52-week low of $41.52 and a 52-week high of $72.13. The company has a market capitalization of $3.86 billion, a PE ratio of 13.34 and a beta of 0.40.

Mednax (NYSE:MD) last issued its earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping the Zacks’ consensus estimate of $0.81 by $0.04. The business had revenue of $843 million for the quarter, compared to analyst estimates of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period last year, the company posted $1.03 earnings per share. On average, equities analysts forecast that Mednax will post $3.31 earnings per share for the current year.

Several research analysts have recently commented on the company. Stephens upgraded Mednax from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $55.00 to $68.00 in a report on Thursday, June 22nd. Jefferies Group LLC reiterated a “hold” rating and issued a $58.00 price objective on shares of Mednax in a report on Wednesday, April 26th. Stifel Nicolaus decreased their price objective on Mednax from $65.00 to $58.00 and set a “hold” rating on the stock in a report on Thursday, May 25th. Zacks Investment Research upgraded Mednax from a “sell” rating to a “hold” rating in a report on Thursday, April 27th. Finally, Mizuho decreased their price objective on Mednax from $64.00 to $58.00 and set a “neutral” rating on the stock in a report on Tuesday, May 30th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $63.00.

TRADEMARK VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/18/mednax-md-earns-daily-news-impact-rating-of-0-15.html.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the sale, the director now directly owns 18,072 shares in the company, valued at $1,040,405.04. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the completion of the sale, the insider now owns 296,379 shares of the company’s stock, valued at $16,300,845. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.